Transforaminal lumbar interbody fusion (TLIF) is widely accepted for the treatment of lumbar arthrodesis. However, the exact characteristics of TLIF depend on the number, location, shape, or materials of the interbody implants, and the type of posterior instrument. Clinical and biomechanical characteristics of each TLIF procedure are still unclear. The present study investigated the clinical and radiological improvements after single level asymmetrical TLIF, in which a single box-shaped spacer was obliquely inserted into the intervertebral space, for lumbar degenerative spondylolisthesis in patients with or without local coronal imbalance (LCI) at the operated level. The clinical records of 60 patients who underwent single level asymmetrical TLIF augmented with the pedicle screw fixation system from January 2005 to January 2011, were retrospectively reviewed. The patients were divided into the LCI group (n = 19) and non-LCI group (n = 41), based on segmental lateral translation or disc wedging at the operated site. Clinical recovery was significantly good in both groups at 2 years after surgery, but improvement of low back pain was significantly worse in the LCI group. Radiological examination revealed that the mean lumbar scoliotic angle was significantly worse in the LCI group postoperatively. Preoperative greater scoliotic angle and coronal off balance of the lumbar spine were related to unfavorable radiological outcomes. The present study showed that single level asymmetrical TLIF is an acceptable method for achieving good clinical and radiological outcomes for patients with symptomatic degenerative spondylolisthesis, however, the clinical benefits and realignment are limited if the patient has LCI at the operated site with greater scoliotic angle or coronal off balance of the lumbar spine.
Objective: Recently, dual-antiplatelet therapy (DAPT) including clopidogrel (CLP) with endovascular treatment for unruptured cerebral aneurysm has been widely accepted. However, patients who are poor metabolizers of CLP (CLPPMs) are more frequent in East Asians than in Caucasians, and an adequate antiplatelet effect may not be achieved with a normal dose in such patients. Prasugrel, which is a novel thienopyridine antiplatelet drug that is less likely to be poorly metabolized than CLP, is used widely for percutaneous coronary intervention, but its efficacy and safety with neuroendovascular treatment have not been elucidated. From this point of view, the purpose of this study was to elucidate the safety and efficacy of prasugrel with endovascular treatment for unruptured cerebral aneurysm. Methods:We investigated 108 consecutive patients with an unruptured cerebral aneurysm who underwent endovascular treatment from March 2015 to January 2016 in our hospital. All patients received DAPT with 100 mg aspirin and 75 mg CLP daily, and antiplatelet function was evaluated by VerifyNow (Accumetrics, San Diego, CA, USA). In patients with P2Y12 reaction units (PRU) over 230, prasugrel was administered with a loading dose of 20 mg and a maintenance dose of 3.75 mg daily.Results: Prasugrel was administered to 12 patients in our series. Of these patients, the mean age was 63.1 ± 13.0 years, and the mean PRU was 272 ± 20. Eleven patients received endovascular treatment with intracranial stents, of which four patients received treatment with flow diverters. The mean observational period was 5-13 months (median: 6.5), and no symptomatic hemorrhagic and ischemic complications occurred. Mean PRU was decreased to 159 ± 63 in the six patients in which PRU were re-examined. Conclusion:Prasugrel is safe and effective with endovascular treatment for unruptured cerebral aneurysm in CLP-PMs.
Objective: Intracranial hemorrhage (ICH) after endovascular revascularization (ER) for acute ischemic stroke is associated with poor outcome. In this study, we examined the risk factors for postoperative ICH in patients who underwent ER in our hospital. Methods:We investigated the incidence/type of postoperative ICH and risk factors in 157 patients who underwent ER in our hospital from July 2011 to June 2015.Results: Postoperative ICH, including asymptomatic ICH, was observed in 57 (36.3%) patients. Symptomatic ICH occurred in seven patients (4.5%). According to the Safe Implementation of Thrombolysis in Stroke-Monitoring Study classification, hemorrhagic infarction type 2 and parenchymal hematoma type 2 were observed in 27 (47.4%) and 4 (7.0%) patients, respectively, of all patients with ICH. The frequency of patients with functional independence (score of 0-2 on the modified Rankin scale) 90 days after ER was significantly lower in patients with than without ICH (p <0.01).We performed a multivariate analysis of factors associated with postoperative ICH. The oral administration of anticoagulants prior to onset (p = 0.019; odds ratio [OR], 3.17; 95% confidence interval [CI], 1.22-8.54) and a prolonged onset-to-recanalization time (p = 0.043; OR, 1.11; 95% CI, 1.01-1.24) were associated with poor outcome.Conclusion: ICH after ER may lead to an unfavorable outcome. Risk factors for ICH after ER included the oral administration of anticoagulants prior to onset and a prolonged onset-to-recanalization time.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.